Complete response of advanced hepatocellular carcinoma to sorafenib : another case and a comprehensive review-Reference-Cited by-同舟云学术

Complete response of advanced hepatocellular carcinoma to sorafenib : another case and a comprehensive review

Published:2017-12-25 Issue:4 Volume:23 Page:340-346
ISSN:2287-2728
Container-title:Clinical and Molecular Hepatology
language:en
Short-container-title:Clin Mol Hepatol

Author:

Kim Tae Suk,Kim Ji Hoon,Kim Baek hui,Lee Young-Sun,Yoo Yang Jae,Kang Seong Hee,Suh Sang-June,Jung Young Kul,Seo Yeon Seok,Yim Hyung Joon,Yeon Jong Eun,Byun Kwan Soo

Publisher

The Korean Association for the Study of the Liver

Subject

Molecular Biology,Hepatology

Link

http://e-cmh.org/upload/pdf/cmh-2016-0070.pdf

Reference20 articles.

1. Sorafenib in Advanced Hepatocellular Carcinoma

2. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

3. Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma

4. A Randomized Phase III Study of Doxorubicin Versus Cisplatin/Interferon α-2b/Doxorubicin/Fluorouracil (PIAF) Combination Chemotherapy for Unresectable Hepatocellular Carcinoma

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Liver Resection and Transplantation in the Era of Checkpoint Inhibitors;JHEP Reports;2024-08

2. The novel predictive nomograms for early death in metastatic hepatocellular carcinoma: A large cohort study;Medicine;2024-01-05

3. Automatic prediction of hepatic arterial infusion chemotherapy response in advanced hepatocellular carcinoma with deep learning radiomic nomogram;European Radiology;2023-07-27

4. Sorafenib as first-line treatment for patients with primary hepatocellular carcinoma: an outcome evaluation;Journal of International Medical Research;2023-06

5. A Practical Nomogram and Risk Stratification System Predicting the Cancer-Specific Survival for Patients With Advanced Hepatocellular Carcinoma;Frontiers in Oncology;2022-07-12